Eckert & Ziegler stock slips on a 4.28 percent weekly drop

Published on 09/15/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock fell 4.28 percent in TecDAX terms as of September 13, 2026. Berenberg keeps a Buy rating at EUR 24.00.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) fell 4.28 percent in TecDAX performance terms in calendar week 37, and that weaker tone framed the shares into September 15, 2026. According to AD HOC NEWS on September 15, 2026, Berenberg still rates the stock Buy with a price target of EUR 24.00.

Chart tone stays weak

The same AD HOC NEWS item said the weekly slide of minus 4.28 percent marked underperformance versus the broader TecDAX, which is the first clear market signal investors saw at the start of the week. The article also tied the move to a cautious short-term technical picture, making the chart the most visible current factor around Eckert & Ziegler.

For context, the company is still part of the TecDAX and SDAX universe, which keeps the stock tied to the German growth segment even when the weekly move turns negative. The Berenberg note referenced by AD HOC NEWS puts the target EUR 24.00 above the recent trading area described in the same report.

What the latest figures say

AD HOC NEWS also summarized the shares as having closed the last visible Xetra session within their intraday range in calendar week 37, with the 4.28 percent weekly performance cited as of September 13, 2026. That gives the stock a dated benchmark for the move and a concrete comparison point against the index.

In a separate market snapshot, Simply Wall St described Eckert & Ziegler as a company with a market capitalization of EUR 772.82 million, medical segment revenue of EUR 171.83 million and isotope products revenue of EUR 148.84 million. It also cited net income of EUR 12 million for Q2 and confirmed full-year 2026 sales guidance at EUR 320 million, giving investors a second set of dated operating figures to weigh against the weaker chart.

EUR 24.00 remains the reference

With Berenberg at Buy and a EUR 24.00 target, the valuation debate now sits next to the 4.28 percent weekly decline and the EUR 772.82 million market value cited in recent coverage. Eckert & Ziegler stock remains driven by the gap between that chart weakness and the still constructive analyst stance.